Abiomed, Inc. – NASDAQ:ABMD

Add to watchlist

$381.02

Market open

Closed in about 1 hour

+48.71%

quarter

+25.10%

year

Market Cap	17.18B
Enterprise value	N/A

P/E	65.35
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	16.09
Price/Book	11.22
PEG ratio	-1.63
EPS	3

Revenue	1.03B
EBITDA	400.78M
Income	136.50M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	24.84%
Oper. margin	23.61%
Gross margin	81.32%
EBIT margin	23.61%
EBITDA margin	38.84%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Abiomed, Inc. (NASDAQ:ABMD): Profit margin
Jun 2021	252.58M	-26.52M	-10.5%
Sep 2021	248.14M	56.95M	22.95%
Dec 2021	261.17M	45.75M	17.52%
Mar 2022	269.85M	60.32M	22.36%

Abiomed, Inc. (NASDAQ:ABMD): Debt to assets
Dec 2021	1592877000	159.93M	10.04%
Mar 2022	1673393000	170.06M	10.16%
Jun 2022	1703636000	167.44M	9.83%
Sep 2022	1696544000	156.75M	9.24%

Abiomed, Inc. (NASDAQ:ABMD): Cash Flow
Jun 2021	55.35M	-109.05M	-7.47M
Sep 2021	60.57M	660K	6.68M
Dec 2021	90.48M	-180.02M	-6.16M
Mar 2022	78.97M	-92.57M	4.74M

Abiomed alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Abiomed
Employees

Abiomed, Inc. (NASDAQ:ABMD): Employee count
Aug 2023	2,003
Sep 2023	2,003
Oct 2023	2,003
Nov 2023	2,003
Dec 2023	2,003
Jan 2024	2,003
Feb 2024	2,003
Mar 2024	2,003
Apr 2024	2,003
May 2024	2,003
Jun 2024	2,003
Jul 2024	2,003

Abiomed
Hedge Funds Holdings Q2 2022

91.86% +0.75%

of ABMD is owned by hedge funds

473 -3

hedge funds hold ABMD stock

42.14M +308.70K

shares is hold by hedge funds

ABMD hedge funds holdings changes

Abiomed, Inc. (NASDAQ:ABMD): Insider trades (number of shares)
Period	Buy	Sel
Jan 2022	0	1000
Feb 2022	0	26325
Mar 2022	0	7500
Apr 2022	0	1000
May 2022	0	4000
Aug 2022	0	5500
Nov 2022	0	11544

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	16 Nov 2022	SUTTER MARTIN P director director	Common Stock, $0.01 par value	141	$375.56	$52,954
Sale	16 Nov 2022	SUTTER MARTIN P director director	Common Stock, $0.01 par value	1,859	$374.66	$696,497
Sale	15 Nov 2022	SUTTER MARTIN P director director	Common Stock, $0.01 par value	867	$374.92	$325,059
Sale	15 Nov 2022	SUTTER MARTIN P director director	Common Stock, $0.01 par value	1,133	$374.18	$423,949
Sale	4 Nov 2022	BEGAN MARC A officer: VP & GEN..	Common Stock, $0.01 par value	2,000	$373.71	$747,420
Sale	4 Nov 2022	BEGAN MARC A officer: VP & GEN..	Common Stock, $0.01 par value	2,000	$373.71	$747,420
Sale	1 Nov 2022	TRAPP TODD A officer: VICE PRE..	Common Stock, $0.01 par value	67	$380.2	$25,473
Sale	1 Nov 2022	TRAPP TODD A officer: VICE PRE..	Common Stock, $0.01 par value	67	$380.2	$25,473
Sale	1 Nov 2022	TRAPP TODD A officer: VICE PRE..	Common Stock, $0.01 par value	191	$379.35	$72,456
Sale	1 Nov 2022	TRAPP TODD A officer: VICE PRE..	Common Stock, $0.01 par value	191	$379.35	$72,456

Status	Patent	Filling date	Issue date
Application	Application SYSTEMS AND METHODS FOR REDUCING LEAKS FROM A CATHETER Filling date: 25 Feb 2022 Issue date: 1 Sep 2022	25 Feb 2022	1 Sep 2022
Application	Application THERMISTOR IMBEDDED THERAPEUTIC CATHETER Filling date: 16 Feb 2022 Issue date: 1 Sep 2022	16 Feb 2022	1 Sep 2022
Grant	Grant Utility: Tree-based data exploration and data-driven protocol Filling date: 4 Oct 2019 Issue date: 23 Aug 2022	4 Oct 2019	23 Aug 2022
Application	Application SYSTEMS AND METHODS FOR DETERMINING CARDIAC PERFORMANCE Filling date: 2 May 2022 Issue date: 18 Aug 2022	2 May 2022	18 Aug 2022
Application	Application SYSTEMS AND METHODS FOR PREDICTING PATIENT HEALTH STATUS Filling date: 19 Apr 2022 Issue date: 4 Aug 2022	19 Apr 2022	4 Aug 2022
Application	Application CANNULA ASSEMBLY Filling date: 16 Feb 2022 Issue date: 4 Aug 2022	16 Feb 2022	4 Aug 2022
Application	Application NETWORK-BASED MEDICAL APPARATUS CONTROL AND DATA MANAGEMENT SYSTEMS Filling date: 24 Sep 2021 Issue date: 7 Jul 2022	24 Sep 2021	7 Jul 2022
Application	Application CRIMP TOOL FOR COMPRESSIBLE CATHETER PUMP Filling date: 28 Dec 2021 Issue date: 30 Jun 2022	28 Dec 2021	30 Jun 2022
Application	Application GRAFT ANCHOR DEVICES, SYSTEMS AND METHODS Filling date: 1 Dec 2021 Issue date: 30 Jun 2022	1 Dec 2021	30 Jun 2022
Grant	Grant Utility: Introducer sheath having a multi-layer hub Filling date: 8 Jun 2020 Issue date: 28 Jun 2022	8 Jun 2020	28 Jun 2022

Abiomed
Earnings Call Transcripts

Quarter	Transcript
Q2 2023 1 Nov 2022	Q2 2023 Earnings Call Transcript
Q1 2023 4 Aug 2022	Q1 2023 Earnings Call Transcript
Q4 2022 28 Apr 2022	Q4 2022 Earnings Call Transcript
Q3 2022 3 Feb 2022	Q3 2022 Earnings Call Transcript

ABMD earnings call transcripts

Abiomed
Executives

Insider	Age	Compensation
Mr. Michael R. Minogue (1967) Chairman, Chief Executive Officer & Pres	58	$2,570,000
Mr. Todd A. Trapp (1971) Chief Financial Officer & Vice President	54	$766,730
Dr. David M. Weber (1961) Senior Vice President & Chief Operating Officer	64	$754,480
Mr. Marc A. Began (1967) Vice President, Gen. Counsel & Sec.	58	$677,860
Mr. Andrew J. Greenfield (1973) Vice President & Chief Commercial Officer	52	$638,670

Abiomed
Latest News

Thursday, 21 March 2024
11:10	US FDA classifies recall of Abiomed's blood pumps as most serious	reuters.com
Thursday, 22 December 2022
09:02	3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio	Zacks Investment Research
Friday, 16 December 2022
05:30	Warren Buffett Loves These Stocks. Should You Buy Them Before 2023?	The Motley Fool
Wednesday, 30 November 2022
08:00	Eleven Stocks Turned $10,000 To $261,421 In 11 Months	Investors Business Daily
Thursday, 10 November 2022
08:37	Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed	The Motley Fool
Saturday, 5 November 2022
07:25	Is Johnson & Johnson's Purchase of Abiomed Good for Investors?	The Motley Fool
06:00	Beat the Dow Jones With This Unstoppable Dividend Stock	The Motley Fool
Tuesday, 1 November 2022
16:49	Why Abiomed Stock Skyrocketed Today	The Motley Fool
15:11	Abiomed Shares Pop 50% on Johnson & Johnson Buyout	GuruFocus
15:04	Abiomed, Inc. (ABMD) Q2 2023 Earnings Call Transcript	Seeking Alpha
14:05	J&J Agrees to Buy Heart-Device Maker Abiomed for $16.6 Billion	WSJ
13:43	Judge blocks Penguin-Simon & Schuster deal, Delta pilots call for strike, J&J to buy Abiomed	Yahoo Finance
12:03	Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down	Zacks Investment Research
10:36	This medical devices stock opened 50% up on Tuesday: here's why	Invezz
09:47	Abiomed (ABMD) Beats Q2 Earnings Estimates	Zacks Investment Research
07:40	J&J to buy Abiomed in $16.6B deal to boost cardiovascular business	Fox Business
07:12	Johnson & Johnson to buy medtech company Abiomed for $380 per share in cash	CNBC Television
07:07	Abiomed Stock Surges on Johnson & Johnson Takeover	Barrons
06:43	Abiomed stock rockets after J&J buyout deal valued at $16.6 billion	Market Watch
Friday, 28 October 2022
14:18	Is Abiomed (ABMD) a Solid Growth Stock? 3 Reasons to Think "Yes"	Zacks Investment Research
Thursday, 27 October 2022
10:33	4 MedTech Stocks Set to Outpace Q3 Earnings Estimates	Zacks Investment Research
Friday, 21 October 2022
14:18	Abiomed's (ABMD) Latest Impella Offering Approved by the FDA	Zacks Investment Research
Thursday, 20 October 2022
13:33	Why Abiomed (ABMD) Could Beat Earnings Estimates Again	Zacks Investment Research
Friday, 7 October 2022
14:18	Abiomed (ABMD) is an Incredible Growth Stock: 3 Reasons Why	Zacks Investment Research
Wednesday, 28 September 2022
13:27	Abiomed: Correction Offers Good Buying Opportunity	Seeking Alpha
Wednesday, 21 September 2022
09:47	Abiomed (ABMD) Posts Impellas Positive Study Results in Japan	Zacks Investment Research
Monday, 19 September 2022
12:47	Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance	Zacks Investment Research
Friday, 2 September 2022
09:47	3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio	Zacks Investment Research
Wednesday, 17 August 2022
14:18	Abiomed's (ABMD) Impella Favored by Latest Study Result	Zacks Investment Research
Monday, 8 August 2022
15:21	Why Shares of Abiomed Rose 18.4% in July	The Motley Fool

Ideas & Opinions

Seeking Alpha 13 Jan 2023

Intuitive Surgical: Valuation Hanging On By The $4 Billion Cash Thread
Seeking Alpha 30 Dec 2022

Amped Up For 2023 With Amplify
Seeking Alpha 28 Dec 2022

Johnson & Johnson: Aspects To Consider After Acquiring Abiomed
Seeking Alpha 19 Dec 2022

Best Idea: Renren And Beyond
Seeking Alpha 2 Nov 2022

Johnson & Johnson Goes Back Into Cardiology With A Big Splash
Seeking Alpha 28 Sep 2022

Abiomed: Correction Offers Good Buying Opportunity
Seeking Alpha 4 Aug 2022

Abiomed: Small Premium For Access To ~11% Normalized ROIC
Seeking Alpha 21 Feb 2022

Riding The Stock Waves: Update On The Medical Devices Sector
Seeking Alpha 10 Sep 2021

Abiomed: Impella Will Continue To Drive Revenue Growth
Seeking Alpha 13 Jul 2021

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Frequently Asked Questions (FAQ)

What's the price of Abiomed stock today?

One share of Abiomed stock can currently be purchased for approximately $381.02.
When is Abiomed's next earnings date?

Unfortunately, Abiomed's (ABMD) next earnings date is currently unknown.
Does Abiomed pay dividends?

No, Abiomed does not pay dividends.
How much money does Abiomed make?

Abiomed has a market capitalization of 17.18B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.74% to 1.03B US dollars.
What is Abiomed's stock symbol?

Abiomed, Inc. is traded on the NASDAQ under the ticker symbol "ABMD".
What is Abiomed's primary industry?

Company operates in the Healthcare sector and Medical - Devices industry.
How do i buy shares of Abiomed?

Shares of Abiomed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Abiomed's key executives?
Abiomed's management team includes the following people:
- Mr. Michael R. Minogue Chairman, Chief Executive Officer & Pres(age: 58, pay: $2,570,000)
- Mr. Todd A. Trapp Chief Financial Officer & Vice President(age: 54, pay: $766,730)
- Dr. David M. Weber Senior Vice President & Chief Operating Officer(age: 64, pay: $754,480)
- Mr. Marc A. Began Vice President, Gen. Counsel & Sec.(age: 58, pay: $677,860)
- Mr. Andrew J. Greenfield Vice President & Chief Commercial Officer(age: 52, pay: $638,670)
How many employees does Abiomed have?

As Jul 2024, Abiomed employs 2,003 workers.
When Abiomed went public?

Abiomed, Inc. is publicly traded company for more then 38 years since IPO on 29 Jul 1987.
What is Abiomed's official website?

The official website for Abiomed is abiomed.com.
Where are Abiomed's headquarters?

Abiomed is headquartered at 22 CHERRY HILL DR, Danvers, MASSACHUSETTS.
How can i contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, Danvers, MASSACHUSETTS and company can be reached via phone at +1 978 777 5410.

Abiomed, Inc.

abiomed.com

Exchange:

NASDAQ

Full time employees:

2,003

Industry:

Medical - Devices

Sector:

Healthcare

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

+1 978 777 5410

22 CHERRY HILL DR
Danvers, MASSACHUSETTS 01923

CIK: 0000815094
ISIN: US0036541003
CUSIP: 003654100